Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation
Chen, Wilbur H
Mulligan, Mark J
Frey, Sharon E
Stapleton, Jack T
Keitel, Wendy A
Johnson, Robert A
Sztein, Marcelo B
JournalClinical & Translational Immunology
PublisherJohn Wiley and Sons Inc.
MetadataShow full item record
AbstractFrancisella tularensis, the causative agent of tularaemia, is an exceptionally infectious bacterium, potentially fatal for humans if left untreated and with the potential to be developed as a bioweapon. Both natural infection and live-attenuated vaccine strain (LVS) confer good protection against tularaemia. LVS vaccination is traditionally administered by scarification, and the formation of a cutaneous reaction or take at the vaccination site is recognised as a clinical correlate of protection. Although previous studies have suggested that high antibody titres following vaccination might serve as a useful surrogate marker, the immunological correlates of protection remain unknown.
Rights/Terms© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14488
- Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.
- Authors: Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB, DMID 08-0006 Tularemia Vaccine Study Group.
- Issue date: 2017 Aug 24
- The tularaemia vaccine.
- Authors: Sandström G
- Issue date: 1994 Apr
- Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).
- Authors: De Pascalis R, Chou AY, Ryden P, Kennett NJ, Sjöstedt A, Elkins KL
- Issue date: 2014 Apr 8
- A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.
- Authors: Jia Q, Bowen R, Sahakian J, Dillon BJ, Horwitz MA
- Issue date: 2013 May
- Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
- Authors: KuoLee R, Harris G, Conlan JW, Chen W
- Issue date: 2007 May 10